ese targets to reassure that Shire can continue to grow despite headwinds to haemophilia. Between this, execution on deleveraging and completion of the Neuroscience Review (at end-17), the share price should recover. • Synergies and deleveraging should offset headwinds in '18, delivering revenue growth. Growth of Imm